TAS 121Alternative Names: TAS-121
Latest Information Update: 08 Jan 2015
At a glance
- Originator Taiho Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
Most Recent Events
- 30 Sep 2014 Phase-I clinical trials in Non-small cell lung cancer in Japan (PO)